Table 2.
Patient and tumor characteristics of patients included in the analysis*
| Category | White patients, % (N = 13 393) | Black patients, % (N = 1218) | P† |
| Cancer stage‡ | |||
| II | 32.6 | 35.1 | .069 |
| III | 67.4 | 64.9 | |
| Sex | |||
| Women | 45.0 | 54.7 | <.01 |
| Men | 55.0 | 45.3 | |
| Age, y | |||
| <40 | 5.5 | 7.6 | <.01 |
| 40–49 | 12.6 | 15.4 | |
| 50–59 | 26.9 | 32.6 | |
| 60–69 | 37.4 | 32.3 | |
| ≥70 | 17.6 | 12.2 | |
| Treatment | |||
| Surgery alone | 9.3 | 14.4 | <.01 |
| 5-FU or MOF | 7.4 | 10.8 | |
| 5-FU + LV or LEV | 71.7 | 64.0 | |
| 5-FU + LV + oxaliplatin/irinotecan | 11.7 | 10.8 |
*
LEV = levamisole; LV = leucovorin; MOF = methyl-(CCNU) and vincristine (Oncovin) and 5-FU; 5-FU = 5-fluorouracil.
†
P values were calculated using a two-sided χ2 test.
‡
Stage II: tumor penetrates beyond the muscularis propria but no lymph node invasion and no other metastases. Stage III: lymph node invasion but no other metastases.